4.6.1.14	2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecyl-phosphonic acid	GPI-1793	57855	
4.6.1.14	Ca2+	activity of GPI-PLC exhibited small but significant inhibition in the presence of calcium ions, 70% activity left	15	
4.6.1.14	Ca2+	weak, 5 mM	15	
4.6.1.14	cetrimide	i.e. alkyltrimethylammonium bromide, 0.3 mg/ml, neutral enzyme form	43910	
4.6.1.14	deoxycholate	neutral enzyme form, above 1 mg/ml, activation at 0.5-1 mg/ml	441	
4.6.1.14	EDTA	-	21	
4.6.1.14	EGTA	Ca2+ reverses, only acidic, not neutral enzyme form	173	
4.6.1.14	EGTA	-	173	
4.6.1.14	Glucosaminyl-alpha-1,6-2-deoxy-D-myo-inositol	i.e. compound VP-615L, more effective than VP-606L	93496	
4.6.1.14	Glucosaminyl-alpha-1,6-D-myo-inositol	i.e. compound VP-606L or 6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-D-myo-inositol	93497	
4.6.1.14	Glucosaminyl-alpha-1,6-D-myo-inositol 1,2-cyclic phosphate	i.e. compound VP-601L, product inhibition	93498	
4.6.1.14	Glucosaminyl-alpha-1,6-D-myo-inositol 1-dodecylphosphonate	i.e. compound VP-604L	93499	
4.6.1.14	Glucosaminyl-alpha-1,6-D-myo-inositol 1-hexylphosphonate	i.e. compound VFT-2	93500	
4.6.1.14	glucosaminyl-alpha-1,6-D-myo-inositol 1-phosphate	i.e. compound VP-600L	93501	
4.6.1.14	Hg2+	10 microM 100% inhibition, 1 microM 67% activity left	33	
4.6.1.14	Inositol 1-dodecylphosphonate	i.e. compound VP-602L	93708	
4.6.1.14	KCl	0.125 M	79	
4.6.1.14	Mannosyl-alpha-1,4-glucosaminyl-alpha-1,6-D-myo-inositol	i.e. O-alpha-D-mannopyranosyl-1,4-O-2-amino-2-deoxy-alpha-D-glucopyranosyl-1,6-D-myo-inositol	96757	
4.6.1.14	Mg2+	weak, 5 mM	6	
4.6.1.14	additional information	no inhibition by IAA	2	
4.6.1.14	additional information	no inhibition by Mn2+	2	
4.6.1.14	additional information	no inhibition by palmitate, myristate, phosphatidylethanolamine, inositol 1-phosphate, N-acetylglucosamine, ethanolamine, inositol, glucosamine, mannose, glucosaminyl-alpha-1,6-2-deoxy-D-myo-inositol 1-phosphate (i.e. VP-612L), glucosaminyl-alpha-1,6-2-deoxy-L-myo-inositol (i.e. VP-614L)	2	
4.6.1.14	additional information	no inhibition by 1,10-phenanthroline	2	
4.6.1.14	additional information	low inhibition by 2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecyl-phosphonic acid (GPI-1793) and very low inhibition by myo-inositol-1-O-dodecylphosphonic acid methylester (GPI-2349)	2	
4.6.1.14	myo-inositol-1,2-cyclo-dodecyl-phosphonic acid	GPI-2350	23561	
4.6.1.14	myo-inositol-1-O-dodecylphosphonic acid methylester	GPI-2349	127527	
4.6.1.14	N-(N,N-Dimethylcarbamyl)-glucosaminyl-alpha-1,6-D-myo-inositol	i.e. compound VC-109B, less effective than VP-606L	96801	
4.6.1.14	N-Acetylglucosaminyl-alpha-1,6-D-myo-inositol	i.e. compound VC-105B, weak	96839	
4.6.1.14	Na3VO4	-	4546	
4.6.1.14	NaCl	0.125 M	42	
4.6.1.14	NaF	-	235	
4.6.1.14	NEM	5 mM	89	
4.6.1.14	NH4Cl	0.125 M	329	
4.6.1.14	Nonidet P-40	above 0.1% w/v, neutral enzyme form	1832	
4.6.1.14	p-chloromercuriphenylsulfonic acid	strong, 5 mM	1416	
4.6.1.14	p-chloromercuriphenylsulfonic acid	-	1416	
4.6.1.14	phosphatidylcholine	weak	215	
4.6.1.14	phosphatidylglycerol	-	681	
4.6.1.14	phosphatidylinositol	-	473	
4.6.1.14	phosphatidylserine	-	430	
4.6.1.14	propanolol	-	5606	
4.6.1.14	sulfhydryl reagents	-	978	
4.6.1.14	Triton X-100	0.05-0.5%, activation at 0.02%	61	
4.6.1.14	Zn2+	100 microM 100% inhibition, 10 microM 59% activity left	14	
4.6.1.14	Zn2+	strong, 5 mM	14	
4.6.1.14	Zn2+	-	14